ISSN: 2462-3547
Jesús K. Yamamoto-Furusho , Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, D.F., Mexico
The advances in the research field of inflammatory bowel disease (IBD) have identified new molecules involved in the etiopathogenesis of IBD and have allowed the development of new therapeutic targets. This review is focused to new treatments recently approved in USA and Europe such as: 1) Topical steroids like MMX budesonide in ulcerative colitis (UC) patients previous to the use of systemic steroids; 2) New 100% human anti tumoral necrosis factor alpha (anti-TNF) antibody named golimumab for its use in patients with UC; 3) Inhibitors of the human integrins such as vedolizumab, who offers good efficacy and security profiles in patients with IBD who have failed to conventional therapy including anti-TNF therapy. Finally, new therapies like ustekinumab and tofacitinib will be incorporated in the treatment algorithm for patients with Crohn´s disease and UC, respectively. Other treatments are under evaluation for efficacy and security in phase 2 studies in order to provide novel therapeutic strategies in patients with IBD.
Keywords: New therapies. Ulcerative Colitis. IBD. Crohn´s Disease.
Full Article in PDF (english) Full Article in PDF (SPANISH)
